Reimbursement Review Reports

The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

Brand Name Sort descending Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Cablivi caplacizumab Acquired thrombotic thrombocytopenic purpura (aTTP) Do not reimburse Complete
Cabometyx Cabozantinib Renal Cell Carcinoma (RCC) Reimburse with clinical criteria and/or conditions Complete
Cabometyx Cabozantinib HCC Reimburse with clinical criteria and/or conditions Complete
Cabometyx cabozantinib Advanced or metastatic renal cell carcinoma Reimburse with clinical criteria and/or conditions Complete
Cabometyx cabozantinib Differentiated thyroid carcinoma Reimburse with clinical criteria and/or conditions Complete
Caduet Amlodipine besylate/ atorvastatin calcium Hypertension/ Dyslipidemia List with clinical criteria and/or conditions Complete
Calquence Acalabrutinib Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL) Reimburse with clinical criteria and/or conditions Complete
Calquence Acalabrutinib Chronic Lymphocytic Leukemia (CLL) Reimburse with clinical criteria and/or conditions Complete
Campral Acamprosate calcium Alcohol Abstinence List with clinical criteria and/or conditions Complete
Campral Acamprosate calcium Alcohol Abstinence N/A Complete
Camzyos mavacamten Obstructive hypertrophic cardiomyopathy Reimburse with clinical criteria and/or conditions Complete
Caprelsa Vandetanib Medullary Thyroid Cancer Reimburse with clinical criteria and/or conditions Complete
Carvykti ciltacabtagene autoleucel Relapsed or refractory multiple myeloma Active
Carvykti ciltacabtagene autoleucel Relapsed or refractory multiple myeloma Reimburse with clinical criteria and/or conditions Complete
Cayston Aztreonam for inhalation solution Cystic fibrosis, chronic pulmonary pseudomonas aeruginosa infections List with clinical criteria and/or conditions Complete
Celsentri Maraviroc HIV Withdrawn
Celsentri Maraviroc HIV List with clinical criteria and/or conditions Complete
Celsentri Maraviroc HIV infection Do not list Complete
Cerdelga Eliglustat Gaucher disease Reimburse with clinical criteria and/or conditions Complete
Champix Varenicline tartrate Smoking-cessation List with clinical criteria and/or conditions Complete
Cibinqo abrocitinib Atopic dermatitis, moderate to severe Reimburse with clinical criteria and/or conditions Complete
Cimzia certolizumab pegol Psoriasis, moderate to severe plaque Reimburse with clinical criteria and/or conditions Complete
Cimzia Certolizumab pegol Ankylosing spondylitis List with criteria/condition Complete
Cimzia Certolizumab pegol Arthritis, psoriatic List with criteria/condition Complete
Cimzia Certolizumab pegol Arthritis, rheumatoid Do not list Complete